Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2013
12/12/2013US20130330424 Non-Medical Increase or Maintenance of Body Weight of a Mammal
12/12/2013US20130330423 Composition to increase joint and/or postural stability
12/12/2013US20130330421 Combinations of therapeutic agents for treating melanoma
12/12/2013US20130330416 Styptic Storage and Delivery
12/12/2013US20130330413 Nutritional compositions comprising chitin microparticles
12/12/2013US20130330412 Smart polymeric nanoparticles which overcome multidrug resistance to cancer therapeutics and treatment-related systemic toxicity
12/12/2013US20130330408 Solid particulate compositions comprising coenzyme q10
12/12/2013US20130330407 Oral formulations and lipophilic salts of methylnaltrexone
12/12/2013US20130330406 Bilayer Tablet Formulations
12/12/2013US20130330405 Method of Making a Soft Gel Capsule Comprising CoQ-10 Solubilized in a Monoterpene
12/12/2013US20130330404 Extended release composition containing tramadol
12/12/2013US20130330403 Diagnosis And Treatment Of Cancers With MicroRNA Located In Or Near Cancer-Associated Chromosomal Features
12/12/2013US20130330400 Systems for treating pulmonary infections
12/12/2013US20130330397 Wound Care Products with Peracid Compositions
12/12/2013US20130330396 Methods for the treatment of throat discomfort
12/12/2013US20130330395 Tyrosine Kinase Microspheres
12/12/2013US20130330392 Polymers Of Fluorinated Monomers And Hydrocarbon Monomers
12/12/2013US20130330380 Topical drug delivery using phosphatidylcholine
12/12/2013US20130330377 C-Met Modulator Pharmaceutical Compositions
12/12/2013US20130330373 Cream composition enhancing skin absorption of glucosamine
12/12/2013US20130330366 Neprilysin inhibitors
12/12/2013US20130330365 Neprilysin inhibitors
12/12/2013US20130330357 METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
12/12/2013US20130330356 METHODS OF TREATING DISORDERS USING HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
12/12/2013US20130330342 Antibody fragments inhibiting hiv nef protein
12/12/2013US20130330332 Treatment of pemphigus
12/12/2013US20130330327 Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines
12/12/2013US20130330326 Methods of treating cancer
12/12/2013US20130330315 Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase
12/12/2013US20130330309 Nutraceutical and pharmaceutical composition
12/12/2013US20130330298 Zeaxanthin-enriched poultry egg
12/12/2013US20130330297 Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
12/12/2013US20130330281 Pharmaceutical Compositions
12/12/2013US20130330277 Methods of using sustained release aminopyridine compositions
12/12/2013US20130327668 Propofol Formulations with Non-Reactive Container Closures
12/12/2013US20130327321 Sublingual fentanyl spray
12/12/2013DE102012105063A1 Stabilizing cannabinoids e.g. cannabidiol, comprises adding additives consisting of compounds that are metal ions complex, free radical scavengers, phenolic groups and/or a compound having basic properties to compounds/compositions
12/12/2013CA2876150A1 Compostions and methods for cancer immunotherapy
12/12/2013CA2876024A1 Neprilysin inhibitors
12/12/2013CA2875979A1 Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
12/12/2013CA2875975A1 Novel iminosugars and their applications
12/12/2013CA2875972A1 5-ala for detection of brain tumors
12/12/2013CA2875970A1 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
12/12/2013CA2875966A1 Compounds and compositions for modulating egfr activity
12/12/2013CA2875799A1 Pyrimidinyl tyrosine kinase inhibitors
12/12/2013CA2875798A1 Methods and compositions for the inhibition of pin1
12/12/2013CA2875767A1 Crystalline forms of an androgen receptor modulator
12/12/2013CA2875692A1 Macrocyclic inhibitors of flaviviridae viruses
12/12/2013CA2875690A1 Macrocyclic inhibitors of flaviviridae viruses
12/12/2013CA2875628A1 Imidazo-oxadiazole and imidazo-thiadiazole derivatives
12/12/2013CA2875624A1 Hiv vaccine
12/12/2013CA2875507A1 Solid forms of an antiviral compound
12/12/2013CA2875446A1 Compositions comprising apomorphine and organic acids and uses thereof
12/12/2013CA2875421A1 Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
12/12/2013CA2875396A1 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease
12/12/2013CA2875330A1 Method of prevention of neurological diseases
12/12/2013CA2875305A1 Fbxo3 inhibitors
12/12/2013CA2875056A1 Methods of treating overweight and obesity
12/12/2013CA2875054A1 Pharmaceutical composition for treating inflammation and pain
12/12/2013CA2875053A1 Pharmaceutical composition for treating inflammation and pain
12/12/2013CA2875052A1 Method for treating skin inflammatory diseases
12/12/2013CA2874968A1 Synergistic therapies of cannabidiol with hypothermia for neuroprotection
12/12/2013CA2874936A1 Vaccine
12/12/2013CA2874851A1 Pharmaceutical compositions for the treatment of cftr-mediated disorders
12/12/2013CA2874850A1 Methods for treating neutropenia using retinoid agonists
12/12/2013CA2874820A1 Solid preparation
12/12/2013CA2874819A1 Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
12/12/2013CA2779883A1 Composition
12/11/2013EP2671949A1 Micro-RNA miR-145 that regulate muscle cell proliferation and differentiation
12/11/2013EP2671888A1 3',5'-cyclic nucleoside phosphate analogues
12/11/2013EP2671887A1 Novel macrolide derivative
12/11/2013EP2671885A1 Imidazo-oxadiazole and Imidazo-thiadiazole derivatives
12/11/2013EP2671884A1 New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
12/11/2013EP2671883A1 New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
12/11/2013EP2671882A1 pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors
12/11/2013EP2671879A1 CYCLIC SULFONIUM SALT, PROCESS FOR PRODUCTION OF SAME, AND alpha-GLUCOSIDASE INHIBITOR COMPRISING SAME
12/11/2013EP2671876A2 Pyrazine derivatives and their use as protein kinase inhbitors
12/11/2013EP2671875A1 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
12/11/2013EP2671872A1 Fluorinated pyridylacetylene derivatives as tracers
12/11/2013EP2671871A1 Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
12/11/2013EP2671870A1 Novel (aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications
12/11/2013EP2671869A1 Tetrahydroisoquinoline derivative
12/11/2013EP2671596A1 Process for producing aqueous solution containing fat-soluble substance
12/11/2013EP2671594A1 Production method for adhesive patch
12/11/2013EP2671593A1 Patch preparation
12/11/2013EP2671590A1 Tegafur-containing composition for single daily and alternate-day dosing
12/11/2013EP2671589A1 Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability
12/11/2013EP2671588A1 Transdermal patch
12/11/2013EP2671587A1 Patch preparation
12/11/2013EP2671586A1 Drug therapy for preventing or treating glaucoma
12/11/2013EP2671585A1 Therapeutic or prophylactic agent for cachexia
12/11/2013EP2671584A2 Compositions and methods for treating disorders associated with salt or fluid retention
12/11/2013EP2671583A1 Externally-used drug for treating skin disorder and method for producing same
12/11/2013EP2671582A1 Ring-fused heterocyclic derivative
12/11/2013EP2671581A2 Compositions and methods for treating cancer
12/11/2013EP2671580A1 Use of antioxidants for the treatment of cognitive and behavioural disorders in individuals with fragile x syndrome
12/11/2013EP2671579A1 Fat and oil composition for promoting insulin secretion
12/11/2013EP2671578A1 Prophylactic or therapeutic drug for peripheral neuropathy caused by anticancer agent
12/11/2013EP2671576A1 Pharmaceutical composition for treating diseases associated with insulin resistance and ß-cell dysfunction
12/11/2013EP2671575A1 Ras inhibitors
1 ... 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 ... 7860